论文部分内容阅读
目的探讨尼莫地平治疗蛛网膜下腔出血的疗效及安全性。方法选取我院治疗的60例蛛网膜下腔出血患者作为研究对象,并随机分为试验组和对照组,各30例。对照组患者使用常规方法治疗,试验组患者在常规治疗基础上给予尼莫地平治疗,观察并比较两组患者的治疗效果、并发症发生率及病死率。结果试验组患者总有效率为93.3%,明显高于对照组的70.0%,差异有统计学意义(P<0.05);试验组患者并发症发生率为6.7%(2/30),病死率为3.3%(1/30);对照组患者并发症发生率为26.7%(8/30),病死率为13.3%(4/30)。试验组并发症发生率、病死率明显低于对照组,差异均有统计学意义(均P<0.05)。结论尼莫地平治疗蛛网膜下腔出血能明显提高治疗效果,并可降低并发症,且安全可靠。
Objective To investigate the efficacy and safety of nimodipine in the treatment of subarachnoid hemorrhage. Methods Sixty patients with subarachnoid hemorrhage treated in our hospital were selected as study subjects and randomly divided into experimental group and control group with 30 cases each. Patients in the control group were treated by conventional methods. Patients in the test group were treated with nimodipine on the basis of conventional treatment. The therapeutic effect, complication rate and mortality of the two groups were observed and compared. Results The total effective rate in the experimental group was 93.3%, which was significantly higher than that in the control group (70.0%, P <0.05). The incidence of complications in the experimental group was 6.7% (2/30) and the mortality was 3.3% (1/30). In the control group, the complication rate was 26.7% (8/30) and the case fatality rate was 13.3% (4/30). The incidence of complication and mortality in the experimental group were significantly lower than those in the control group (all P <0.05). Conclusion Nimodipine in the treatment of subarachnoid hemorrhage can significantly improve the therapeutic effect, and can reduce complications, and safe and reliable.